AstraZeneca

H1 and Q2 2024 Results

Fixed-income investor update

25 July 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

Disclaimer

This presentation is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which an offer, solicitation, or sale is unlawful.

Non-GAAP measures

This presentation contains financial measures that are not calculated in accordance with generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include net debt as well as our core financial measures and constant exchange rate (CER) growth rates. Non-GAAP measures included in this presentation should be considered in addition to, but not as substitutes for, the information we prepare in accordance with GAAP and as a result should be reviewed in conjunction with our financial statements. We provide reconciliations on slides 31 and 32 in the Appendix to this presentation between our non-GAAP financial measures and the respective most directly comparable financial measure calculated and presented in accordance with GAAP. However, the Company presents Core EPS guidance only at CER. It is unable to provide guidance on a Reported/GAAP basis because the Company cannot reliably forecast material elements of the Reported/GAAP result, including the fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions.

Key messages

H1 2024 - Strong commercial performance

Total revenue growth of 18%

Strong pipeline momentum to date in H1 2024

Investing in new launches, near and mid-term pipeline

Strong portfolio and pipeline supports 2030 ambition

Multiple high-value medicines to drive leading grow

Balanced and diversified company

By therapy area and geography

Financial execution – focus on operating margin expansion and cash flow

FY 2024 guidance upgraded

All growth rates at CER

Business update

H1 2024 – strong underlying growth, Total Revenue +18%

Total Revenue | 18% CER



Core Operating Profit | 7% CER



Core EPS | 5% CER



Upgraded FY 2024 guidance – Total Revenue and Core EPS expected to increase by mid teens percentage

All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Appendix: Glossary.

H1 2024 – very strong performance across diverse, broad-based business

Continued growth across key geographies

H1 2024 Total Revenue, $m



Double-digit growth across key therapy areas

H1 2024 Total Revenue[1], $m



1. Other Medicines delivered $573m in Total Revenue in H1 2024..

All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals.

Appendix: Glossary.

Significant pipeline momentum in H1 2024

Key positive Phase III readouts

ADRIATIC	LAURA	DESTINY-Breast06	ECHO	NIAGARA
Imfinzi potential first IO therapy in LS-SCLC	***Tagrisso*** expanding in early-stage *EGFR*m NSCLC	***Enhertu*** moving into CTx naïve mBC, benefit in HER2-ultralow	***Calquence*** first BTKi to show favourable OS trend in 1L MCL	***Imfinzi*** potential first IO regimen to extend survival in MIBC

Transformative new approvals and launches
First region approved

Tagrisso + CTx	*Enhertu*	*Ultomiris*	*Airsupra*	*Imfinzi*
FLAURA2 reinforces ***Tagrisso*** as TKI backbone in 1L NSCLC	Tumour agnostic approval expands ***Enhertu*** in solid tumours	Expanding ***Ultomiris*** in neurology with NMOSD approval	***Airsupra*** is first ICS/SABA combination treatment for asthma	***Imfinzi*** approval for endometrial patients with mismatch repair deficient disease, based on DUO-E

Collaboration partner: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

Oncology – H1 and Q2 2024

Total Revenue +22% in H1 2024 driven by global demand for key medicines

Oncology

H1 2024 $10.4bn, +22%



Q2 2024: key dynamics

- ***Tagrisso*** +12%, ADAURA, FLAURA and FLAURA2 strong global demand
- ***Calquence*** +22%, sustained BTKi leadership in 1L CLL
- ***Imfinzi*** +18%, demand growth, offset by JP repricing effective February 2024
- ***Imjudo*** +19%, continued HCC (HIMALAYA) and NSCLC (POSEIDON) growth
- ***Lynparza*** **PS** +7%, continued PARPi leadership
- ***Enhertu*** +49%, continued demand in HER2+ (DB03) and HER2-low (DB04), encouraging early launch in tumour agnostic
- ***Truqap*** n/m, strong adoption in biomarker-altered population

- New indications: US (*Imfinzi* DUO-E), EU (*Truqap* CAPI-291, *Tagrisso* FLAURA2), JP (*Tagrisso* FLAURA2), CN (*Tagrisso* FLAURA2)

All growth rates at CER.

Collaboration partners: Daiichi Sankyo (*Enhertu*), Merck & Co., Inc. (*Lynparza*).

Appendix: Glossary.

Oncology – R&D highlights

Positive readouts expand AstraZeneca presence across key tumour types

Practice changing data at ASCO and EHA

LAURA — *Tagrisso* first targeted therapy to show benefit in *EGFR*m Stg. III u/r NSCLC[1] NCCN GUIDELINES updated

ADRIATIC — *Imfinzi* first IO to demonstrate overall survival benefit in limited-stage SCLC[2]

DESTINY-Breast06 — *Enhertu* redefining HER2 expression, moving earlier into chemo-naïve setting[3]

ECHO — *Calquence* first BTKi to show favourable trend on survival in untreated MCL[4]

Expanding oncology leadership into bladder cancer

NIAGARA – first IO regimen before and after surgery to extend survival in muscle-invasive bladder cancer



Robust bladder development programme with *Imfinzi*

POTOMAC | H1 2025 — **VOLGA** | H2 2025 — **NILE** | H2 2024

NMIBC → MIBC → metastatic

'First' denotes firsts in Phase III global trials. 1. Ramalingam SS et al. Abstract LBA4 presented at American Society of Clinical Oncology 2024; 2. Spigel DR et al. Abstract LBA5 presented at American Society of Clinical Oncology 2024; 3. Curigliano G et al. Abstract LBA1000 presented at American Society of Clinical Oncology 2024; 4. Wang M et al. Abstract LB3439 presented at European Hematology Association 2024.

Collaboration partner: Daiichi Sankyo (*Enhertu*).

Appendix: Glossary.

BioPharmaceuticals – H1 and Q2 2024

Total Revenue $10.4bn, +17% – demand growth, accelerating new launch momentum

CVRM

H1 2024 $6.2bn, +22%



R&I

H1 2024 $3.8bn, +22%



Q2 2024: key dynamics

- ***Farxiga*** +32%, strong global demand growth
- ***Wainua*** n/m**,** accelerating new patient starts
- ***Breztri*** +47%, increased share in growing class
- ***Tezspire*** >2x, continued growth in US, increasing new patient share EU, JP and EM
- ***Airsupra*** n/m**,** encouraging launch uptake
- ***Symbicort*** 25%, underlying demand growth in EM and US

All growth rates at CER.

Collaboration partners: Amgen (*Tezspire*); Sanofi (*Beyfortus*); Ionis (*Wainua*).

Appendix: Glossary.

BioPharmaceuticals – R&D highlights

Positive readouts build confidence in CVRM pipeline multi-blockbuster potential

$5bn+*

AZD0780 (oPCSK9) | Phase I[1] dyslipidaemia



AZD0780 showed additional 52% LDL-C reduction on top of SoC statin

Potential best-in-class profile – oral once-daily dosing and no interaction with food

Phase IIb data anticipated H1 2025

$3-5bn*

balcinrenone/dapagliflozin FDC | Phase IIb MIRACLE[2] HF with CKD



- Only ~25% heart failure with CKD patients receive SoC MRAs due to hyperkalaemia risk
- **balci/dapa FDC reduced UACR without increasing hyperkalaemia**

BalanceD-HF Phase III readout anticipated >2025

*Peak Year Revenue, non-risk adjusted as disclosed on Investor Day 21 May 2024.

1. Vega RB, et al. presented at European Atherosclerosis Society Congress; May 26-29; Lyon, France 2024; 2. Lam CSP et al. Eur J Heart Failure 2024 (in press).

Appendix: Glossary.

Rare Disease – H1 and Q2 2024

Total Revenue +15% in H1 2024 driven by neurology

Rare Disease

H1 2024 $4.2bn, +15%



Q2 2024: key dynamics

C5 Franchise: sustainable, durable growth

- ***Ultomiris*** +36%, driven by demand growth in neurology indications (gMG, NMOSD)
- ***Soliris*** (8%), continued rapid conversion to *Ultomiris*, partly offset by growth in Emerging Markets

---

Beyond Complement: market expansion and increased demand

- ***Strensiq*** +14% and ***Koselugo*** +45%, driven by continued global demand

All growth rates at CER.
1. Includes *Kanuma* and *Koselugo*.
Collaboration partners: Merck & Co., Inc. (*Koselugo*).
Appendix: Glossary.

Rare Disease – R&D highlights

Amolyt Pharma acquisition completed, eneboparatide Phase III anticipated H1 2025



eneboparatide | hypoparathyroidism

A rare endocrine disorder characterised by deficient or absent parathyroid hormone

$1-3bn*

Epidemiology

US
106K

EU5
105K

JP
42K

80% of hypoparathyroidism patients are women

>50% are peri- or post-menopausal women



75% post-neck surgery

25% genetic, autoimmune, idiopathic

Eneboparatide binds to PTH 1 receptor

- Normalising serum calcium levels
- Decreasing urinary calcium excretion
- Preserving bone mineral density

Phase III CALYPSO
data anticipated in H1 2025

US Breakthrough Designation | US Orphan Drug Designation

Amolyt acquisition expands Alexion's presence in rare endocrinology

*Peak Year Revenue, non-risk adjusted as disclosed on Investor Day 21 May 2024.

Appendix: Glossary.

Delivering leading growth and long-term value creation

Ambition to deliver **$80bn in Total Revenue by 2030**[1]

On track to deliver **mid-30s% Core operating margin by 2026**

Beyond 2026, Core operating margin will be influenced by portfolio evolution and the Company will target at least mid-30s%

Ambition to deliver **at least 20 NMEs by 2030**

1. 2030 Total Revenue ambition at CER, risk adjusted and not dependent upon future M&A. Appendix: Glossary.

Multiple high-value medicines to drive leading growth

Existing medicines and NME opportunities with $5bn+ potential

Existing portfolio

- *Wainua*
- *Farxiga*
- *Imfinzi/ Imjudo*
- *Tagrisso*
- *Enhertu*
- *Ultomiris*

NME opportunities

- camizestrant
- Dato-DXd
- rilvegostomig
- volrustomig
- saruparib
- AZD0486
- AZD0120
- AZN ADCs
- dapa FDCs
- baxdrostat
- AZD0780
- weight management

AstraZeneca on track to deliver 25+ blockbusters by 2030

Collaboration partners: Daiichi Sankyo (*Enhertu* and Dato-DXd); Compugen (rilvegostomig); Ionis (*Wainua*)
Appendix: Glossary.

AstraZeneca – rich catalyst path and confidence building news-flow supports long-term growth ambition

H2 2024 Phase III readouts and data presentations

- Dato-DXd – **TB02** – TNBC
- *Imfinzi* – **NILE** – 1L metastatic bladder
- *Truqap* – **CAPItello-281**– d*PTEN* HSPC
- *Tezspire* – **WAYPOINT** – CRwNP
- *Koselugo* – **KOMET** – NF1-PN (adults)

Key Phase III readouts anticipated in 2025

- camizestrant – **SERENA-6** – HR+/HER2- mBC
- Dato-DXd – **AVANZAR** – 1L NSCLC
- *Enhertu* – **DB11** – early HER2+ mBC
- *Enhertu* – **DB09** – 1L HER2+ mBC
- *Imfinzi* – **MATTERHORN** – GC/GEJC
- *Imfinzi* – **POTOMAC** – NMIBC
- *Imfinzi* – **VOLGA** – cis-ineligible MIBC
- baxdrostat – **BaxHTN** – uncontrolled HTN
- *Fasenra* – **RESOLUTE** – COPD
- anselamimab – **AL amyloidosis**
- eneboparatide – **CALYPSO** – hypopara.

2024 data build confidence in high-value, disruptive categories – IO bispecifics, ADCs, weight management

Collaboration partners: Daiichi Sankyo (*Enhertu* and Dato-DXd); Amgen (*Tezspire*); Merck (*Koselugo*)
Appendix: Glossary.

Financial update

H1 and Q2 2024 – Reported profit and loss



	H1 2024 $m	CER change %	% Total Revenue	Q2 2024 $m	CER change %	% Total Revenue
Total Revenue	**25,617**	**18**	**100**	**12,938**	**17**	**100**
- Product Sales	*24,629*	*18*	*96*	12,452	*18*	*96*
- Alliance Revenue	*939*	*50*	*4*	482	*42*	*4*
- Collaboration Revenue	*49*	*(78)*	-	4	*(98)*	-
Product Sales Gross Margin[1]	82.1%	-		82.5%	-	
Total operating expense[2]	(15,482)	7	60	(8,069)	5	62
- R&D expense	(5,791)	10	23	(3,008)	13	23
- SG&A expense	(9,424)	6	37	(4,929)	1	38
Other operating income and expense	127	(89)	-	60	(92)	-
Operating profit	5,861	25	23	2,746	20	21
Tax rate	21%			20%		
Reported EPS	**$2.65**	**23**		**$1.24**	**15**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 2. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

H1 and Q2 2024 – Core profit and loss



	H1 2024 $m	CER change %	% Total Revenue	Q2 2024 $m	CER change %	% Total Revenue
Total Revenue	**25,617**	**18**	**100**	**12,938**	**17**	**100**
- Product Sales	*24,629*	*18*	*96*	12,452	*18*	*96*
- Alliance Revenue	*939*	*50*	*4*	482	*42*	*4*
- Collaboration Revenue	*49*	*(78)*	-	4	*(98)*	-
Product Sales Gross Margin[1]	82.4%	-1pp		82.7%	-	
Total operating expense[2]	(12,985)	15	51	(6,739)	14	52
- R&D expense	(5,570)	15	22	(2,872)	13	22
- SG&A expense	(7,148)	15	28	(3,735)	16	29
Other operating income and expense	125	(89)	-	60	(92)	-
Operating profit	8,411	7	33	4,101	1	32
Tax rate	20%			19%		
Core EPS	**$4.03**	**5**		**$1.98**	**(3)**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 2. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Net debt and capital expenditure

Net cash inflow from operating activities increased 15% in H1 2024

Net debt bridge



Capital expenditure

- Anticipate ~50% increase in tangible capex in 2024, due to investment in capacity and capabilities
- Tangible capex $799m in H1 2024, reflects maintenance and new investments:
  - API facility in Ireland
  - Inhaled manufacturing site in Qingdao, CN
  - Cell therapy manufacturing site in Rockville, MD
- Planned end-to-end ADC manufacturing site in Singapore announced in May 2024

Net debt/Adjusted EBITDA 1.8x

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1.Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. The Company uses Debt issuance to finance new Business Development opportunities 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $59m (FY 2023: $114m). AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. If foreign exchange rates for July to December were to remain at the average rates seen in June 2024. Appendix: Glossary.

Global demand growth across leading medicines

Top medicines by H1 2024 Total Revenue

	Total Revenue $ million	Growth vs. PY CER%
Farxiga	3,836	38%
Tagrisso	3,203	13%
Imfinzi	2,259	25%
Ultomiris	1,804	35%
Calquence	1,508	28%
Symbicort	1,491	19%
Lynparza	1,450	9%
Soliris	1,439	-8%
Enhertu	932	62%
Fasenra	781	6%
Strensiq	653	18%

Strong underlying growth supports upgraded FY 2024 guidance

Collaboration partners: Daiichi Sankyo (*Enhertu*), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

FY 2024 guidance

Upgraded FY 2024 guidance at CER reflecting strong underlying performance

Total Revenue

- **Mid teens percentage increase**
  (previously low double-digit to low teens)

Core EPS

- **Mid teens percentage increase**
  (previously low double-digit to low teens)

Other guidance indications

- An increase in Collaboration Revenue is not assumed in the upgraded guidance
- Other operating income is expected to decrease substantially (FY 2023 included a $241m gain on the disposal of *Pulmicort Flexhaler* US rights, and a $712m one-time gain relating to updates to contractual arrangements for *Beyfortus*)
- Core Tax Rate is expected to be between 18-22%

Anticipated FX impact – low single-digit adverse impact on Total Revenue and mid single-digit adverse impact on Core EPS[1]

1. If foreign exchange rates for July 2024 to December 2024 were to remain at the average rates seen in June 2024.

Appendix: Glossary.

Net debt position

	30-Jun-24 $m	31-Dec-23 $m
Gross debt	(33,533)	(28,622)
Cash & cash equivalents	6,916	5,840
Other investments	160	122
Net derivative financial instruments	133	150
Closing net debt [1]	**(26,324)**	**(22,510)**

1. Net debt is a non-GAAP measure. The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma share purchase liability of $nil (31 December 2023: $833m). Further details are available in our Q2 results announcement published on 25 July 2024.

Liquidity, debt and rating summary

- Strong liquidity at 30 June 2024:
  - Group cash and investments of $7.1bn
  - Undrawn $6.9bn committed bank facilities: $2bn mature in February 2025 and $4.9bn mature in April 2029

- Access to diverse sources of funding through US and European term debt and commercial paper programmes

Programme	Last Updated	Valid to	Limit	Rating (Moody's / S&P)	Utilisation as at 30/6/2024 [1]
SEC Shelf Registration Statement	Mar-24	Mar-27	Unlimited	A2 / A	USD 23.5bn
Euro Medium Term Note Programme	Jun-24	Jun-25	USD 10bn	A2 / A	USD 3.8bn
US Commercial Paper	N/A	N/A	USD 15bn	A-1 / P-2	USD 2.5bn
Euro-Commercial Paper	May-20	N/A	EUR 10bn	Issuer rating	None

[1] Notional bond values. FX converted at 30 June 2024 spot rates (USD/EUR 0.935; USD/GBP 0.791)

- The Board continues to target a strong, investment-grade credit rating

- The Company is currently rated as:
  - Moody's: A2 Stable outlook / P1
  - Standard & Poor's: A Stable outlook / A1

Smooth debt maturity profile with seven-year average life

Debt Maturity Profile at 30 June 2024 [1]



1. Notional bond values. FX converted at 30 June 2024 spot rates (USD/EUR 0.935; USD/GBP 0.791). Current portion of leases of $292m are included in 2024, whilst non-current leases of $949m have been excluded from the chart.

Appendix & Glossary

- Glossary
- Oncology tumour maps
- Reported to Core reconciliation
- Treasury policy



Glossary – abbreviations

ADC	antibody conjugate
API	active pharmaceutical ingredient
ASCO	American society of clinical oncology
ASCO	American Society of Clinical Oncology
ATTR-PN	transthyretin amyloid polyneuropathy
bn	billions
BTD	break through designation
BTD	break through designation
BTKi	Bruton's tyrosine kinase
C5	complement component 5
CER	Constant exchange rates
CFO	cash flow from operating activities
cis	cisplatin
CKD	chronic kidney disease
CN	China
CRwNP	chronic rhinosinusitis with nasal polyps
CTLA-4	cytotoxic T-lymphocyte associated protein 4
CTx	chemotherapy
CVRM	Cardiovascular, renal and metabolism
dPTEN	phosphatase and tensin homolog deficient
EBITDA	Earnings before interest, tax, depreciation and amortisation
*EGFR*m	epidermal growth factor receptor mutant
EHA	European Hematology Association
EM	Emerging Markets
EPS	Earnings per share
EPS	earnings per share
ERoW	Established rest of world
ET	endocrine therapy
EU5	France, Germany, Italy, Spain, and UK
FDC	fixed dose combination
FX	Foreign exchange
GC	gastric cancer
GEJC	gastroesophageal junction cancer
gem	gemcitabine
Gluc	glucagon
gMG	generalised myasthenia gravis
HCC	Hepatocellular carcinoma
HER2+	human epidermal growth factor receptor 2 positive
HER2-low	human epidermal growth factor receptor 2 low
HR+	hormone receptor positive
HTN	hypertension
ICS	inhaled corticosteroid
IL5	Interleukin 5
IO	Immuno-oncology
IO	Immuno-oncology
JP	Japan
K+	Potassium
LA	long-acting
LDL-C	low-density lipoprotein cholesterol
m	millions
mBC	Metastatic breast cancer
MCL	mantle cell lymphoma
MIBC	muscle invasive bladder cancer
MRM	mineralocorticoid receptor modulator
n/m	Not material
NF1-PN	neurofibromatosis type 1-plexiform neurofibromas
NME	new molecular entity
NMIBC	non-muscle invasive bladder cancer
NMOSD	Neuromyelitis optica spectrum disorder
NSCLC	Non-small cell lung cancer
ODD	orphan drug designation
ODD	orphan drug designation
oGLP1	oral glucagon-like receptor peptide 1
OOI	other operating income
oPCSK9	oral protein convertase subtilisin/kexin type 9
OS	overall survival
PARPi	poly-ADP ribose polymerase inhibitor
PD1	programmed cell death protein 1
PD-L1	programmed cell death ligand 1
PTH	parathyroid hormone
QCS	quantitative continuous scoring
R&D	research and development
R&I	Respiratory and immunology
R&I	respiratory and immunology
SABA	short acting beta agonist
SCLC	small cell lung cancer
SG&A	sales, general and administrative
SGLT2i	sodium/glucose cotransporter 2 inhibitor
SoC	standard of care
Stg I/II/III	Stage 1/2/3
TIGIT	T-cell immunoreceptor with immunoglobulin and ITIM domains
TIM-3	T-cell immunoglobulin and mucin domain-containing protein
TKI	tyrosine kinase inhibitor
TNBC	triple negative breast cancer
u/r	unresectable / resectable
UACR	urinary albumin/creatinine ratio
V&I	Vaccines and Immune Therapies

AstraZeneca in Lung Cancer

Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030

	resectable	unresectable		metastatic	
	Stg. I-III	Stg. I-II	Stg. III	1L	2L+
Est. epi (G7)	~200K	~30K	~70K	~350K	~290K
IO sensitive c.70%	*Imfinzi* **AEGEAN**	*Imfinzi / Osi* w/ SBRT **PACIFIC-4**	CRT → *Imfinzi* **PACIFIC**	*Imfinzi* + *Imjudo* + CTx **POSEIDON**	*Imfinzi* + ceralasertib **LATIFY**
	volrustomig + CTx *Imfinzi* + Dato + plat **NEOCOAST-2**		*Imfinzi* combos **PACIFIC-8, -9** improvements across PD-L1 spectrum	Dato-DXd + IO +/- Platinum **TROPION-Lung08/TROPION-Lung07/AVANZAR**	Dato-DXd **TROPION-Lung01**
				Dato-DXd + Rilvegostomig **TROPION-Lung10**	AZD9592 (EGFR/cMET ADC) **EGRET**
				Enhertu + IO + CTx **DESTINY-Lung03**	
				volrustomig + CTx **eVOLVE-Lung02**	sabestomig (PD-1/TIM3)
*EGFR*m c.16%	*Tagrisso* **ADAURA**		CRT → *Tagrisso* **LAURA**	*Tagrisso* **FLAURA**	savolitinib + *Tagrisso* **SAFFRON/SAVANNAH**
	Tagrisso **neoADAURA**			*Tagrisso* + *CTx* **FLAURA-2**	Dato-DXd +/- *Tagrisso* **TROPION-Lung15/ 01**
				Dato-DXd + *Tagrisso* **TROPION-Lung14**	AZD9592 (EGFR/cMET ADC) **EGRET**
Other tumour drivers c.12%			CRT → *Imfinzi* **PACIFIC**		
*HER2*m c.2%				*Enhertu* **DESTINY-Lung04**	*Enhertu* **DESTINY-Lung02**

established SoC

Leading the future of lung cancer treatment

- Establishing *Tagrisso* as backbone TKI in *EGFR*m
- *Imfinzi* leading IO in unresectable
- Advancing best-in-class ADCs to replace systemic chemotherapy
- Delivering next-wave bispecifics to improve on PD1/PD-L1
- Developing novel combinations, including IO + ADCs
- Investing behind new technologies and platforms, including cell therapy and testing/screening

Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Compugen (rilvegostomig).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death



All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Q2 2024 Reconciliation of Reported to Core Financial Measures

	Reported $m	Restructuring $m	Intangible Asset Amortisation & Impairments $m	Other[1] $m	Core[2] $m
Gross Profit	10,755	16	9	-	10,780
Distribution Expense	(132)	-	-	-	(132)
R&D Expense	(3,008)	97	35	4	(2,872)
SG&A Expense	(4,929)	41	943	210	(3,735)
Other Operating Income & Expense	60	-	-	-	60
Operating Profit	2,746	154	987	214	4,101
Net Finance Expense	(343)	-	-	58	(285)
Taxation	(469)	(35)	(185)	(52)	(741)
Earnings Per Share	$1.24	$0.08	$0.51	$0.15	$1.98

1. Further details are available in our Q2 results announcement published on 25 July 2024.
2. Each of the measures in the Core column in the above table are non-GAAP financial measures.

H1 2024 Reconciliation of Reported to Core Financial Measures

	Reported $m	Restructuring $m	Intangible Asset Amortisation & Impairments $m	Other[1] $m	Core[2] $m
Gross Profit	21,216	36	19	-	21,271
Distribution Expense	(267)	-	-	-	(267)
R&D Expense	(5,791)	177	39	5	(5,570)
SG&A Expense	(9,424)	138	1,884	254	(7,148)
Other Operating Income & Expense	127	(2)	-	-	125
Operating Profit	5,861	349	1,942	259	8,411
Net Finance Expense	(645)	-	-	115	(530)
Taxation	(1,089)	(80)	(368)	(71)	(1,608)
Earnings Per Share	$2.65	$0.17	$1.01	$0.20	$4.03

1. Further details are available in our Q2 results announcement published on 25 July 2024.
2. Each of the measures in the Core column in the above table are non-GAAP financial measures.

Prudent treasury risk-management policies

The Company operates with a centralised Treasury structure so that key Treasury risks are managed at a Group level.

Liquidity Policy
- Prudent level of available cash and unutilised credit facilities
- Group funding centrally managed

Investment policy
- Security and liquidity
- Financial counterparty limits

Foreign Exchange Policy
- Foreign Exchange exposures managed centrally
- Transactional currency exposures substantially hedged

Interest Rate Policy
- Aim to broadly match level of floating rate debt to cash over time
- Significant portion of financial liabilities at fixed interest rates

Credit Risk
- Cash managed centrally
- Derivatives positions predominately cash collateralised